Ignite Creation Date:
2025-12-24 @ 12:22 PM
Ignite Modification Date:
2026-01-04 @ 2:13 PM
Study NCT ID:
NCT02187861
Status:
COMPLETED
Last Update Posted:
2019-06-05
First Post:
2014-07-09
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-12-01
Start Date Type:
ACTUAL
Primary Completion Date:
2016-09-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-03-16
Completion Date Type:
ACTUAL
First Submit Date:
2014-07-09
First Submit QC Date:
None
Study First Post Date:
2014-07-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-09-15
Results First Submit QC Date:
None
Results First Post Date:
2017-10-13
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-06-03
Last Update Post Date:
2019-06-05
Last Update Post Date Type:
ACTUAL